

**AGENDA**

Caesars Palace, Las Vegas, Nevada, USA

Wednesday, February 24<sup>th</sup>

3:00-6:00 pm *Registration desk open*

6:30 pm **Opening Dinner**.....Bradley Ogden Restaurant

Thursday, February 25<sup>th</sup>

6:30 am *Registration desk open*

7:00-8:00 am Breakfast.....Octavius 5&6

8:00-8:15 **Welcome:** Leon and Debra Black, MRA Co-Founders.....Octavius 1-4  
**Introduction:** Wendy KD Selig, MRA President and Chief Executive Officer

8:15-9:35 **MRA award reports: Biological factors driving melanoma carcinogenesis**  
Session Chair: Boris Bastian, MD

8:15-8:35 The novel melanoma oncogene GNAQ provides new opportunities for therapeutic intervention:  
Boris Bastian, MD, University of California, San Francisco

8:35-8:55 A genome-wide association study to identify melanoma predisposition genes:  
Nicholas G Martin, PhD, Queensland Institute for Medical Research

8:55-9:15 Genetics of melanoma metastasis: Daniel Pinkel, PhD, University of California, San Francisco

9:15-9:35 Synthetic lethality to MAP kinase pathway inhibition in BRAF-mutant melanoma:  
Levi Garraway, MD, PhD, Dana-Farber Cancer Institute

9:35-10:00 **Regression of melanomas in patients by inhibiting activated BRAF with PLX4032**  
Paul Chapman, MD, Memorial Sloan-Kettering Cancer Center

10:00-10:15 *Break*

10:15-12:00 **Leveraging technologies for improved cutaneous melanoma detection**  
Session Chair: Allan Halpern, MD

10:15-10:30 The challenge and promise of technologies for melanoma detection:  
Allan Halpern, MD, Memorial Sloan-Kettering Cancer Center

10:30-11:20 Individual Technologies:

Computerized diagnostic system: Laura Korb Ferris, MD, PhD, University of Pittsburgh,  
Electro-Optical Sciences

Genetic-based detection system: William Wachsman, MD, PhD, University of California,  
San Diego / San Diego VA and Scientific Advisory Board, DermTech International

Remote sensing technology: Clara Curiel, MD, Arizona Cancer Center, Raytheon Company /  
University of Arizona collaboration

Electronic biopsy: Ulrik Birgersson, SciBase AB

Real-time confocal microscopy: Kelly Nelson, MD, Duke University; Lucid

11:20-11:45 Perspective: Martin Weinstock, MD, PhD, Brown University and Rhode Island Hospital

11:45-12:00 Discussion and Q&A

12:00-1:30 **Lunch**.....Octavius 5&6

1:30-2:50 **MRA award reports: Advancing immunotherapeutic and surgical approaches  
for melanoma treatment**.....Octavius 1-4  
Session Chair: Victor Engelhard, PhD

1:30-1:50 MHC-associated phosphopeptides as targets for melanoma immunotherapy:  
Victor Engelhard, PhD, University of Virginia

1:50-2:10 Platform for MHC-exchange based T cell therapy for melanoma:  
Ton Schumacher, PhD, The Netherlands Cancer Institute

2:10-2:30 Immunologic signatures of response to Ipilimumab:  
Jedd Wolchok, MD, PhD, Memorial Sloan-Kettering Cancer Center

2:30-2:50 Surgery and immunotherapy for melanoma metastatic to distant sites:  
Donald Morton, MD, John Wayne Cancer Institute

## Thursday, February 25<sup>th</sup> (cont.)

### 2:50-3:40 **MRA award reports: Featuring the 2008 Young Investigators**

Session Chair: Laura Brockway-Lunardi, PhD, MRA Scientific Program Director

2:50-2:55 Introduction

2:55-3:10 Targeting CD4+ T cells for melanoma immunotherapy: Timothy Bullock, PhD, University of Virginia

3:10-3:25 Regulation of T cell chemokine receptor expression during vaccination: Tumor-targeted immunotherapy: David Mullins, PhD, University of Virginia

3:25-3:40 Defining the role of inducible co-stimulator (ICOS)-expressing T cells against melanoma: Padmanee Sharma, PhD, MD Anderson Cancer Center

3:40-4:00 *Break*

### 4:00-4:45 **Nutrition and cancer - Approaches for melanoma research**

David Heber, MD, PhD, University of California, Los Angeles

4:45-4:50 **Summary:** Suzanne Topalian, MD, MRA Chief Science Officer

### 5:30-8:00 pm **Reception and Entertainment**.....Terrace and Octavius 1-4

Remarks by Mike Milken, *FasterCures* Chairman and MRA Board Member

Featuring a special performance by Australian popular vocal quartet, Human Nature

*Dinner on your own*

## Friday, February 26<sup>th</sup>

6:30 am *Registration desk open*

7:00-8:00 am Breakfast.....Octavius 5&6

8:00 am **Introduction:** Suzanne Topalian, MD.....Octavius 1-4

### 8:05-9:45 **MRA award reports: Targeting cellular and molecular pathways for melanoma therapeutics**

Session Chair: Jonathan Cebon, MD

8:05-8:25 Therapeutic targeting of melanoma stem cells: Jonathan Cebon, MBBS, FRACP, MD, Ludwig Institute for Cancer Research, Melbourne Center for Clinical Sciences

8:25-8:45 Systemic MFG-E8 blockade as melanoma therapy:  
Glenn Dranoff, MD, Dana-Farber Cancer Institute

8:45-9:05 Accelerating melanoma therapy: Genomics, drug screening and informatics:  
Dave Hoon, PhD, John Wayne Cancer Institute

9:05-9:25 Therapeutic inhibition of mutant activated signaling pathways in melanoma:  
Neal Rosen, MD, PhD, Memorial Sloan-Kettering Cancer Center

9:25-9:45 A pathway to rational combination therapies for melanoma: Synthetic lethal screening with small molecule inhibitors, guided by phosphoproteome analysis:  
Michael Weber, PhD, University of Virginia

### 9:45-10:15 **Mapping the melanoma genome - Current knowledge and future directions towards prevention and treatment**

Lynda Chin, MD, Dana-Farber Cancer Institute

10:15-10:30 *Break*

### 10:30-12:00 **Developing experimental drug combinations - Opportunities and challenges**

Session Co-chairs: Drew Pardoll, MD, PhD, Johns Hopkins University and Rachel Humphrey, MD, Bristol-Myers Squibb

Panelists:

David Bonk, Esq, Bristol-Myers Squibb

Kathleen Dohoney, PhD, Novartis Institutes for BioMedical Research, Inc.

James Doroshov, MD, U.S. National Cancer Institute

Mark Ratain, MD, University of Chicago

12:00 **Concluding remarks:** Wendy Selig

12:00 pm Lunch (available for carry-out).....Octavius 5&6